“Backed by Science” – What does it Mean?

“有科学依据”是什么意思？

许多公司销售“有科学依据”的产品，但无论作为科学家还是非科学家，想要去鉴定这些科学证据的质量都可能十分困难。 

在科学/证据方面，与其它国家相比，我们在新西兰的产品包装上所能展示的内容受到限制。我们现行的法规制定于 20 世纪 80 年代，早已过时。 

在加拿大等国家，我们可以根据支持我们产品的科学依据以及完善的注册流程，提出截然不同的声明，这种流程既能保障消费者安全，又能支持功效型产品的销售。

在研发既有效又安全的产品时，在科学和技术层面有许多需要考量的地方：

  1. 哪些生物活性成分有最好的证据支持我们想要达到的健康成果？
  2. 这些生物活性成分如何协同作用——它们是互补的还是拮抗的？
  3. 我们如何将这些生物活性成分制成某种剂型，使其在整个生产过程中保持生物活性？
  4. 我们如何去除霉菌和酵母，同时又不破坏成分的生物活性？这尤其重要，因为购买产品的客户往往是免疫功能受损的人群。
  5. 我们以何种形式呈现产品，使其既方便使用，又能保持稳定和有效？
  6. 我们信任哪些原料/生物活性成分供应商，以确保我们的生物活性成分来源安全且高质量？
  7. 我们如何持续改进产品，并对其进行技术和临床测试？

我们引以为豪的是，我们非常重视产品背后的科学与技术质量。 

我们并没有止步不前，目前正在生理学家和肺科医生的支持下设计合作临床试验，以收集关于我们 Zestt Breathe+ 系列产品的进一步科学数据——我们将在今年年底前获得结果。

我们还与最高质量的原料供应商合作，例如 Blis Technologies，他们的口腔益生菌产品背后拥有广泛的科学研究支持。以下是我们所使用的两种口腔益生菌成分 BlisK12 和 BlisM18 所依托的部分科学研究参考资料。我们在 Zestt Breathe+ 和 Zestt Gut+ 含片中使用 BlisK12，在 Zestt Cardio+ 含片中使用 BlisM18。我们在 Zestt Oral+ 含片中同时使用了 BlisK12 和 BlisM18（这是我们所知的唯一一款同时含有这两种口腔益生菌的产品）。 

如果您想了解更多关于这些研究的信息，请随时告诉我们。

  1. Di Pierro, F., Donato, G., Fomia, F., Adami, T., Careddu, D., Cassandro, C., & Albera, R. (2012). Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media. International Journal of General Medicine, 5, 991–997. https://doi.org/10.2147/IJGM.S38859
  2. Di Pierro, F., Adami, T., Rapacioli, G., Giardini, N., & Streitberger, C. (2013). Clinical evaluation of the oral probiotic Streptococcus salivarius K12 in the prevention of recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes in adults. Expert Opinion on Biological Therapy, 13(3), 339–343. https://doi.org/10.1517/14712598.2013.758711
  3. Di Pierro, F., Colombo, M., Zanvit, A., Risso, P., & Rottoli, A. S. (2014). Use of Streptococcus salivarius K12 in the prevention of streptococcal and viral pharyngotonsillitis in children. Drug, Healthcare and Patient Safety, 6(1), 15–20.  https://doi.org/10.2147/dhps.s59665
  1. Di Pierro, F., Colombo, M., Zanvit, A., & Rottoli, A. S. (2016). Positive clinical outcomes derived from using Streptococcus salivarius K12 to prevent streptococcal pharyngotonsillitis in children: a pilot investigation. Drug, Healthcare and Patient Safety, 8, 77 -81. https://doi.org/10.2147/DHPS.S117214
  2. Di Pierro, F., Colombo, M., Giuliani, M. G., Danza, M. L., Basile, I., Bollani, T., Conti, A. M., Zanvit, A., & Rottoli, A. S. (2016). Effect of administration of Streptococcus salivarius K12 on the occurrence of streptococcal pharyngo-tonsillitis, scarlet fever and acute otitis media in 3 years old children. European Review for Medical and Pharmacological Sciences, 20(21), 4601–4606.
  3. Di Pierro, F., Risso, P., Poggi, E., Timitilli, A., Bolloli, S., Bruno, M., Caneva, E., Campus, R., & Giannattasio, A. (2018). Use of Streptococcus salivarius K12 to reduce the incidence of pharyngo-tonsillitis and acute otitis media in children: A retrospective analysis in not-recurrent pediatric subjects. Minerva Pediatrica, 70(3), 240–245. https://doi.org/10.23736/ S0026-4946.18.05182-4
  4. Gregori, G., Righi, O., Risso, P., Boiardi, G., Demuru, G., Ferzetti, A., Galli, A., Ghisoni, M., Lenzini, S., Marenghi, C., Mura, C., Sacchetti, R., & Suzzani, L. (2016). Reduction of group A beta-hemolytic streptococcus pharyngotonsillar infections associated with use of the oral probiotic Streptococcus salivarius K12: a retrospective observational study. Therapeutics and Clinical Risk Management, 12, 87. https://doi.org/10.2147/TCRM.S96134
  5. Marini, G., Sitzia, E., Panatta, M. L., & de Vincentiis, G. C. (2019). Pilot study to explore the prophylactic efficacy of oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngo-tonsillar episodes in pediatric patients. International Journal of General Medicine, 12, 213–217. https://doi.org/10.2147/IJGM.S168209
  6. Wang, Q., Lin, X., Xiang, X., Liu, W., Fang, Y., Chen, H., Tang, F., Guo, H., Chen, D., Hu, X., Wu, Q., Zhu, B., & Xia, J. (2021). Oropharyngeal Probiotic ENT-K12 Prevents Respiratory Tract Infections Among Frontline Medical Staff Fighting Against COVID-19: A Pilot Study. Frontiers in Bioengineering and Biotechnology, 9. https://doi.org/10.3389/fbioe.2021.646184
  1. Campanella, V., Syed, J., Santacroce, L., Saini, R., Ballini, A., & Inchingolo, F. (2018). Oral probiotics influence oral and respiratory tract infections in pediatric population: a randomized double-blinded placebo-controlled pilot study. European Review for Medical and Pharmacological Sciences, 22(22), 8034–8041. https://doi.org/10.26355/ EURREV_201811_16433
  2. Guo, H., Xiang, X., Lin, X., Wang, Q., Qin, S., Lu, X., Xu, J., Fang, Y., Liu, Y., Cui, J., & Li, Z. (2022). Oropharyngeal Probiotic ENT-K12 as an Effective Dietary Intervention for Children With Recurrent Respiratory Tract Infections During Cold Season. Frontiers in Nutrition, 9. https://doi.org/10.3389/ fnut.2022.900448
  1. Di Pierro, F., & Colombo, M. (2021). The administration of S. salivarius K12 to children may reduce the rate of SARS-CoV-2 infection. In Minerva Medica (Vol. 112, Issue 4, pp. 514–516). Edizioni Minerva Medica. https://doi.org/10.23736/S0026-4806.21.07487-5
  1. Di Pierro, F., Iqtadar, S., Mumtaz, S. U., Bertuccioli, A., Recchia, M., Zerbinati, N., & Khan, A. (2022). Clinical Effects of Streptococcus salivarius K12 in Hospitalized COVID-19 Patients: Results of a Preliminary Study. Microorganisms, 10(10), 1926. https://doi.org/10.3390/microorganisms10101926
  1. La Torre, F., Sota, J., Insalaco, A., Conti, G., del Giudice, E., Lubrano, R., Breda, L., Maggio, M. C., Civino, A., Mastrorilli, V., Loconte, R., Natale, M. F., Celani, C., Romeo, M., Patroniti, S., Gentile, C., Vitale, A., Caggiano, V., Gaggiano, C., … Rigante, D. (2023). Preliminary data revealing efficacy of Streptococcus salivarius K12 (SSK12) in Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Adenitis (PFAPA) syndrome: A multicenter study from the AIDA Network PFAPA syndrome registry. Frontiers in Medicine, 10. https://doi.org/10.3389/ fmed.2023.1105605
  1. Laws, G. L., Hale, J. D. F., & Kemp, R. A. (2021). Human Systemic Immune Response to Ingestion of the Oral Probiotic Streptococcus salivarius BLIS K12. Probiotics and Antimicrobial Proteins. https://doi.org/10.1007/s12602-021-09822-3
  2. Laws, G. A., Harold, L. K., Tagg, J. R., & Hale, J. D. F. (2022). Interferon Gamma Response in Human Saliva Following Exposure to the Oral Probiotic Streptococcus salivarius BLIS K12. Probiotics and Antimicrobial Proteins. https://doi.org/10.1007/ S12602-022-10010-0
  1. Bertuccioli, A., Gervasi, M., Annibalini, G., Binato, B., Perroni, F., Rocchi, M. B. L., Sisti, D., & Amatori, S. (2023). Use of Streptococcus salivarius K12 in supporting the mucosal immune function of active young subjects: A randomised double-blind study. Frontiers in Immunology, 14. https://doi.org/10.3389/ 2023.1129060
  2. Burton, J. P., Chilcott, C. N., Moore, C. J., Speiser, G., & Tagg, J. R. (2006). A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters. Journal of Applied Microbiology, 100(4), 754–764. https://doi.org/10.1111/j.1365-2672.2006.02837.x
  3. Jamali, Z., Aminabadi, N. A., Samiei, M., Deljavan, A. S., Shokravi, M., & Shirazi, S. (2016). Impact of chlorhexidine pretreatment followed by probiotic streptococcus salivarius strain K12 on halitosis in children: A randomised controlled clinical trial. Oral Health and Preventive Dentistry, 14(4), 305–313. https://doi.org/10.3290/j.ohpd.a36521
  4. Hu, L., Mao, Q., Zhou, P., Lv, X., Hua, H., & Yan, Z. (2019). Effects of Streptococcus salivarius K12 with nystatin on oral candidiasis—RCT. Oral Diseases, 25(6), 1573–1580. https://doi.org/10.1111/odi.13142
  5. Poorni, S., Nivedhitha, M., Srinivasan, M., & Balasubramaniam, (2022). Effect of Probiotic Streptococcus salivarius K12 and M18 Lozenges on the Cariogram Parameters of Patients With High Caries Risk: A Randomised Control Trial. https://doi.org/10.7759/cureus.23282
  6. Tandelilin, ReginaT. C., Widita, E., Agustina, D., & Saini, R. (2018). The effect of oral probiotic consumption on the caries risk factors among high-risk caries population. Journal of International Oral Health, 10(3), 132. https://doi.org/10.4103/ jioh_82_18
  7. Benic, G. Z., Farella, M., Morgan, X. C., Viswam, J., Heng, N. C., Cannon, R. D., & Mei, L. (2019). Oral probiotics reduce halitosis in patients wearing orthodontic braces: a randomized, triple-blind, placebo-controlled trial. Journal of Breath Research, 13(3), 36010. https://doi.org/10.1088/1752-7163/ AB1C81
  8. Bardellini, E., Amadori, F., Gobbi, E., Ferri, A., Conti, G., & Majorana, A. (2020). Does streptococcus salivarius strain M18 assumption make black stains disappear in children? Oral Health and Preventive Dentistry, 18(2), 161–164. https://doi.org/10.3290/j.ohpd.a43359
  9. Salim, H. P., Mallikarjun, S. B., Raju, S., & Surendranath, R. (2023). Randomized Clinical Trial of Oral Probiotic Streptococcus salivarius M18 on Salivary Streptococcus mutans in Preprimary Children. International Journal of Clinical Pediatric Dentistry, 16(2), 259–263. https://doi.org/10.5005/jpjournals-10005-2527
  10. Burton, J. P., Drummond, B. K., Chilcott, C. N., Tagg, J. R., Thomson, W. M., Hale, J. D. F., & Wescombe, P. A. (2013). Influence of the probiotic Streptococcus salivarius strain M18 on indices of dental health in children: A randomized double-blind, placebo-controlled trial. Journal of Medical Microbiology. https://doi.org/10.1099/jmm.0.056663-0
  11. Di Pierro, F., Zanvit, A., Nobili, P., Risso, P., & Fornaini, C. (2015). Cariogram outcome after 90 days of oral treatment with Streptococcus salivarius M18 in children at high risk for dental caries: results of a randomized, controlled study. Clinical, Cosmetic and Investigational Dentistry, 7, 107–113. https://doi.org/10.2147/CCIDE.S93066
  12. Scariya, L., Nagarathna, D. v, & Varghese, M. (2015). Probiotics in periodontal therapy. International Journal of Pharma and Bio Sciences, 6(1), P242-P250.
  13. Kiselnikova, L. P., & Toma, E. I. (2022). 长期摄入益生菌对龋齿学龄前儿童主要牙科参数的影响。《儿科牙科与牙科预防》，22(2)，97–102。 https://doi.org/10.33925/1683-3031-2022-22-2-97-102
  14. Babina, K., Salikhova, D., Doroshina, V., Makeeva, I., Zaytsev, A., Uvarichev, M., Polyakova, M., & Novozhilova, N. (2023). 含唾液链球菌M18菌株的口腔益生菌对牙龈炎和牙菌斑的缓解作用：一项随机临床试验。《营养素》，15(18)，3882。https://doi.org/10.3390/nu15183882
  15. Burleigh, M. C., Rosier, B. T., Simpson, A., Sculthorpe, N., Henriquez, F., & Easton, C. (2023). 益生菌唾液链球菌M18可增加血浆亚硝酸盐水平但不会改变血压：一项试点随机对照试验。《应用微生物学》，3(3)，774–785。 https://doi.org/10.3390/ applmicrobiol3030054
  16. Burton, J. P., Wescombe, P. A., Moore, C. J., Chilcott, C. N., & Tagg, J. R. (2006). 口腔益生菌唾液链球菌的安全性评估，《应用与环境微生物学》。 https://doi.org/10.1128/AEM.72.4.3050-3053.2006
  1. Burton, J. P., Chilcott, C. N., Wescombe, P. A., & Tagg, J. R. (2010). 口腔益生菌唾液链球菌的扩展安全性数据，《益生菌与抗菌蛋白》，2(3)，135–144。 https://doi.org/10.1007/s12602-010-9045-4
  1. Burton, J. P., Cowley, S., Simon, R. R., McKinney, J., Wescombe, P. A., & Tagg, J. R. (2011). 口腔益生菌唾液链球菌K12的安全性与人体耐受性评估：一项随机、安慰剂对照、双盲研究。《食品与化学毒理学：英国工业生物研究协会国际期刊》，49(9)，2356–2364。 https://doi.org/10.1016/j.fct.2011.06.038
  1. Burton, J. P., Wescombe, P. A., Macklaim, J. M., Chai, M. H. C., MacDonald, K., Hale, J. D. F., Tagg, J., Reid, G., Gloor, G. B., & Cadieux, P. A. (2013). 口腔益生菌唾液链球菌M18的持续性具有剂量依赖性，且巨型质粒转移可增强其细菌素生产和粘附特性。《公共科学图书馆：综合》，8(6)。https://doi.org/10.1371/journal.pone.0065991

 祝好，Anna 和 Darcy。

如果您想进一步讨论相关内容，请联系 Darcy 或 Anna（电话分别为 +64 27 599 2255 或 +64 27 4861418），或发送邮件至 info@zesttwellness.com。

返回博客